Go Pro
→ Gold buyout deals have handed shareholders overnight gains up to 79 percent (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$0.00
$0.00
▼
$0.01
$10K-12.39693 shsN/A
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
$0.00
$0.00
$0.00
▼
$1.51
$10K14.3178 shs25 shs
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$0.00
-66.7%		$0.01
$0.00
▼
$0.06
N/A0.585,784 shs2,767 shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00%-50.00%0.00%-50.00%-80.00%
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
0.00%+1,900.00%+17.65%-35.48%-98.00%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
0.00%-66.67%-99.00%-99.67%-99.38%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%-60.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
$0.00
$0.00
▼
$0.01
$10K-12.39693 shsN/A
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
$0.00
$0.00
$0.00
▼
$1.51
$10K14.3178 shs25 shs
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$0.00
-66.7%		$0.01
$0.00
▼
$0.06
N/A0.585,784 shs2,767 shs
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$0.00
$0.00
▼
$0.05
$10K1.767,146 shsN/A
7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00%-50.00%0.00%-50.00%-80.00%
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
0.00%+1,900.00%+17.65%-35.48%-98.00%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
0.00%-66.67%-99.00%-99.67%-99.38%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00%0.00%0.00%0.00%-60.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
0.00
N/AN/AN/A
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
0.00
N/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
0.00
N/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/AN/A
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
$2.89M0.00N/AN/AN/A∞
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$10K0.42N/AN/A($0.77) per share0.00
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
$8.13K0.00N/AN/AN/ANaN
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/AN/A
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
-$4.96MN/AN/AN/AN/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
-$2.08M-$0.16N/AN/AN/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
-$15.18M-$0.21N/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/AN/AN/AN/AN/A
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
N/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
N/A
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
22.24%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
0.01%

Insider Ownership

CompanyInsider Ownership
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
20.20%
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
25.70%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
23.52%
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
43.68%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acura Pharmaceuticals, Inc. stock logo
ACUR
Acura Pharmaceuticals
1066.65 million53.19 millionNot Optionable
China Liberal Education Holdings Limited stock logo
CLEUF
China Liberal Education
303.37 million2.50 millionNot Optionable
Kaya Holdings, Inc. stock logo
KAYS
Kaya
441.57 million31.80 millionNot Optionable
Navidea Biopharmaceuticals, Inc. stock logo
NAVB
Navidea Biopharmaceuticals
10100.08 million56.37 millionNo Data

Recent News About These Companies

Navidea Biopharmaceuticals Files for Chapter 11 Bankruptcy
October 9, 2025  |  contractpharma.comC
Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
October 8, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20251008843839/en/navidea-biopharmaceuticals-inc.-files-for-bankruptcy/
AIG rejects D&O claim as Navidea directors sue over legal bills
September 2, 2025  |  insurancebusinessmag.comI
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
May 21, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250520421964/en/navidea-biopharmaceuticals-inc.-announces-extension-of-authority-to-implement-a-reverse-stock-split/
Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
March 31, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250331822538/en/navidea-biopharmaceuticals-announces-the-extension-of-plan-designed-to-protect-nols-and-other-tax-assets/
Navidea Biopharmaceuticals Inc. (NAVB) Latest Pre Market Trades
December 23, 2024  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/navb/pre-market-trades
Navidea Biopharmaceutical (OTC:NAVB) Stock Quotes, Forecast and News Summary
October 28, 2024  |  benzinga.comhttps://www.benzinga.com/quote/NAVB
Navidea Biopharmaceuticals gets grant for treatment of flaviviridae family virus infections
August 22, 2024  |  pharmaceutical-technology.comP
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
July 3, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240703199069/en/navidea-biopharmaceuticals-inc.-announces-results-of-exploratory-analysis-completed-on-july-2-2024/
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
June 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240620380826/en/navidea-biopharmaceuticals-inc.-announces-special-meeting-of-stockholders-to-be-held-july-8-2024/
SK Biopharmaceuticals Co. Ltd.
May 25, 2024  |  wsj.comhttps://www.wsj.com/market-data/quotes/KR/326030/financials
Day One Biopharmaceuticals, Inc. Common Stock (DAWN)
May 3, 2024  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/dawn
Navidea Biopharmaceuticals files patent for polymeric compound for treating diseases involving macrophages
March 6, 2024  |  pharmaceutical-technology.comP
Navidea Biopharmaceuticals gets grant for method for conjugating metal chelating agent to functionalized dextran
March 5, 2024  |  pharmaceutical-technology.comP
Navidea Biopharmaceutical Stock (OTC:NAVB), Short Interest Report
February 23, 2024  |  benzinga.comhttps://www.benzinga.com/quote/NAVB/short-interest
Navidea Biopharmaceutical Stock (OTC:NAVB) Dividends: History, Yield and Dates
February 22, 2024  |  benzinga.comhttps://www.benzinga.com/quote/NAVB/dividend
Navidea Biopharmaceutical Stock (OTC:NAVB) Insider Trades
February 22, 2024  |  benzinga.comhttps://www.benzinga.com/quote/NAVB/insider-trades
Central Ohio public company voluntarily deregisters stock
January 29, 2024  |  bizjournals.comhttps://www.bizjournals.com/columbus/news/2024/01/29/navidea-sec-stock-deregister.html
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
January 26, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/navidea-biopharmaceuticals-inc-files-form-000500004.html?.tsrc=rss
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
January 26, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/navidea-biopharmaceuticals-inc-files-form-000500004.html?.tsrc=rss

Media Sentiment Over Time

Acura Pharmaceuticals stock logo

Acura Pharmaceuticals OTCMKTS:ACUR

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.

China Liberal Education stock logo

China Liberal Education OTCMKTS:CLEUF

$0.0020 0.00 (0.00%)
As of 08/14/2026

China Liberal Education Holdings Limited provides educational services and products under the China Liberal brand name in the People's Republic of China. The company offers Sino-foreign jointly managed academic programs, including undergraduate and postgraduate education; and diploma and non-degree higher education, and senior secondary education programs in the areas of languages, liberal arts, and businesses. It also provides overseas study consulting and technological consulting services for Chinese universities to enhance their campus information and data management system, as well as to optimize their teaching, operating, and management environment. The company's consulting services include campus intranet solution buildout, school management software customization, smart devices, installation and testing, and school management data collection and analysis. In addition, it sells textbooks and other course materials, and AI-space products to students enrolled under the Sino-foreign Jointly Managed Academic Programs, as well as offers job readiness training to graduating students. China Liberal Education Holdings Limited was founded in 2011 and is headquartered in Beijing, the People's Republic of China.

Kaya stock logo

Kaya OTCMKTS:KAYS

$0.0001 0.00 (-66.67%)
As of 08/14/2026 12:42 PM Eastern

Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.

Navidea Biopharmaceuticals stock logo

Navidea Biopharmaceuticals NYSE:NAVB

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas